Alzheimer’s drug developers are now at the forefront of adopting more nuanced, cost-effective, and patient-centric clinical trial designs.

Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.